NTRA Natera Inc

Vontobel Holding Ltd. significantly increased its stake in Natera, Inc. (NASDAQ:NTRA) by 192.5% in the third quarter of 2025, now holding 8,531 shares valued at approximately $1.37 million. This move comes despite recent heavy insider selling, including significant sales by directors Roy Baynes and Herm Rosenman. Wall Street analysts maintain a generally positive outlook on Natera, with a consensus "Moderate Buy" rating and an average target price of $231.18.

SWS Partners increased its stake in Natera, Inc. (NASDAQ:NTRA) by 11.8% to 47,037 shares in Q3, making it their 12th largest holding. Despite significant insider selling and an EPS miss, analysts maintain a "Moderate Buy" consensus with a target price of $231.18, driven by strong revenue growth. Other institutional investors also increased their holdings in Natera during the same period.

J.P. Morgan raised its price target for Natera, Inc. (NTRA) from $250 to $260, maintaining an Overweight rating, citing strong operational momentum and the rapid adoption of its Signatera molecular residual disease (MRD) test. This optimism is reinforced by Barclays maintaining its Overweight rating with a $270 price target and Jefferies raising its target to $275. Recent clinical validation and Natera's acquisition of Foresight Diagnostics further strengthen its position in oncology diagnostics and recurring revenue potential.

Zevenbergen Capital Investments LLC reduced its stake in Natera, Inc. by selling 11,417 shares, now owning 394,565 shares worth approximately $63.5 million. Natera's latest quarterly revenue of $592.2 million beat expectations, but it missed on EPS, reporting a loss of $0.64. Despite significant insider selling and negative margins, analysts maintain a "Moderate Buy" rating with an average price target of $229.12.

This article is empty. It appears to be a cookie consent page or an incomplete article focusing solely on legal disclaimers. There is no substantive content regarding Natera (NTRA), trial data, or Signatera's risk reduction in CRC.

Natera (NTRA) has seen a significant surge, returning 425.8% over three years, with recent developments fueling bullish sentiment despite its high valuation. A Discounted Cash Flow (DCF) analysis suggests it is 10.4% undervalued, projecting substantial free cash flow growth. However, its Price to Sales ratio of 14.69x is higher than industry averages and its proprietary "Fair Ratio" of 8.21x, indicating it might be overvalued based on fundamental metrics.